Core Insights - Zimmer Biomet Holdings, Inc. reported second quarter net sales of $1.942 billion, reflecting a 3.9% increase year-over-year and a 5.6% increase on a constant currency basis [1] - The company achieved diluted earnings per share of $1.18 and adjusted diluted earnings per share of $2.01 for the second quarter [1] - The company updated its 2024 reported revenue guidance due to currency expectations while reaffirming its constant currency revenue growth and adjusted earnings per share guidance [1][7] Financial Performance - Net earnings for the second quarter were $242.8 million, with adjusted net earnings of $415.0 million [1][15] - For the six months ended June 30, 2024, net sales totaled $3.831 billion, a 3.5% increase compared to the same period in 2023 [16] - The company reported operating profit of $351.3 million for the second quarter, up from $329.6 million in the prior year [15] Geographic and Product Category Sales - In the United States, net sales were $1.106 billion, a 3.5% increase, while international sales reached $835.8 million, a 4.4% increase [5] - The knees product category saw total sales of $801.1 million, with U.S. sales at $441.2 million and international sales at $359.9 million [5] - The hips product category reported total sales of $506.5 million, with U.S. sales at $259.0 million and international sales at $247.5 million [5] Financial Guidance - The updated guidance for 2024 reported revenue change is now projected at 4.0% - 5.0%, down from the previous 4.5% - 5.5% [7] - The constant currency revenue change guidance remains at 5.0% - 6.0%, and adjusted diluted EPS guidance is reaffirmed at $8.00 - $8.15 [7] Management Commentary - The CEO highlighted strong Q2 performance driven by customer demand for diversified products and the strength of the international business [3] - The company is making progress against key priorities, including operational excellence and innovation [3]

Wall Street analysts forecast that Zimmer Biomet (ZBH) will report quarterly earnings of $1.98 per share in its upcoming release, pointing to a year-over-year increase of 8.8%. It is anticipated that revenues will amount to $1.94 billion, exhibiting an increase of 3.7% compared to the year-ago quarter. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of ...

Zimmer Biomet Holdings, Inc. (ZBH) is scheduled to report second-quarter 2024 results on Aug 7, before market open. In the last reported quarter, the company's earnings of $1.94 exceeded the Zacks Consensus Estimate by 3.74%. Over the trailing four quarters, its earnings outperformed the consensus estimate on three occasions and matched the same once, the average beat being 2.46%. Q2 Estimates The Zacks Consensus Estimate for second-quarter 2024 revenues is pegged at $1.94 billion, suggesting a 3.7% rise fr ...

Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (888) 204- 4368 and using conference ID 5103691. International callers should dial +1 (323) 994-2093 and use conference ID 5103691. SOURCE Zimmer Biomet Holdings, Inc. Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital an ...

PhonlamaiPhoto Zimmer Biomet's (NYSE:ZBH) share price has been under considerable pressure over the past 3 months, potentially due to a combination of soft growth, poor cash flows and higher interest rates. Some of these issues are expected to begin correcting later in the year though. I previously suggested that concerns over the impact of weight loss drugs was misplaced, with reduced obesity rates likely to provide a demand boost in the near term. The rise of robotic surgeries and Zimmer's evolving produc ...

WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (Nasdaq: EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are plea ...

Zimmer Biomet (ZBH) and RevelAi Health accepted a multi-year co-marketing agreement to commercialize generative artificial intelligence (AI)-powered engagement solutions, which, in turn, should help the advancement of value-based orthopedic care and health equity. More on the Partnership About RevelAi Health It offers a unique patient care management system, managing text messages and clinician-guided voice agents to enhance patient engagement. Industry Prospects Simultaneously, the global value-based healt ...

Zimmer Biomet Holdings, Inc. (ZBH) entered into a limited distribution agreement with Think Surgical Inc. to expand its knee surgery product business. Per the terms of the agreement, Zimmer Biomet will offer Think Surgical's wireless, handheld TMINI - Miniature Robotic System for total knee arthroplasty. More in the News As ZBH's core focus remains on advancing technologies for total knee replacement, this collaboration should help strengthen Zimmer Biomet's position in this market. About TMINI Image Source ...

RevelAi Health is a software as a service (SAAS) health technology company that specializes in cutting-edge generative AI population health solutions. RevelAi Health's clinician-validated large language model helps healthcare providers transition seamlessly to value-based care, meeting essential CMS (Centers for Medicare & Medicaid Services) requirements, including Patient Reported Outcome measures and Social Drivers of Health (SDOH) Screening. For more information about this partnership and the technologie ...

--TMINI System Complements Company's Flagship ROSA® Robotics Portfolio Featuring Applications for Knee, Hip and Shoulder Arthroplasty-- "We are proud to be the first medtech company to offer two complementary robotic systems for surgeons looking to incorporate robotic assistance while performing a knee replacement," said Dr. Nitin Goyal, Chief Science, Technology and Innovation Officer at Zimmer Biomet. "TMINI addresses surgeon demand for an ergonomic, wireless, handheld robotic system and now, in addition ...